Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep32 | Adrenal and Cardiovascular Endocrinology | ECE2022

Interference in aldosterone assay revealed by hemolysis.

Deckers Martine , Klooker Tamira , Hillebrand Jacquelien , van den Berg Sjoerd , de Bie Prim

We report an interference in an immunoassay for aldosterone, which potentially could have led to a wrongful diagnosis and unnecessary surgery. The interference was serendipitously recognized due to a preanalytical error. A 59-year-old female patient with hypertension was referred to the department of endocrinology after an adrenal incidentaloma was detected. Because of her hypertensive history, screening for primary hyperaldosteronism was performed. An elevated aldosterone and...

ea0070aep154 | Bone and Calcium | ECE2020

Psychiatric Comorbidities in Chronic Hypoparathyroidism – a German Single-Center Analysis in 107 Patients

Teresa Fuss Carmina , Hermes Franca , Koschker Ann-Cathrin , Unterecker Stefan , Deckert Jürgen , Hahner Stefanie

Introduction: Reduction of quality of life in patients with chronic hypoparathyroidism (HPT) has been reported by several studies. Additionally, self-report data point to a higher prevalence of anxiety disorders in HPT compared to patients after thyroidectomy.Objectives: To characterize psychiatric diseases in a systematically reviewed cohort of patients with chronic HPT.Methods: We systematically assessed psychiatric comorbidities...

ea0026p263 | Pituitary | ECE2011

Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant

Chieffo C , Ryan M , Bai S , Hu X , Decker S , Quandt H , Frohman L , Gadelha M

Two randomized open-label, phase II studies evaluated an octreotide hydrogel implant to suppress serum GH and IGF1 levels in adult acromegaly patients. Implants were inserted subcutaneously in the upper arm for 6 months. Patients in study 1 received 1 (n=5) or 2 (n=6) 52-mg octreotide (60 mg octreotide acetate) hydrated implants; patients in study 2 received a hydrated (H) or nonhydrated (NH) 84-mg octreotide acetate implant (n=34, 1 excluded from efficacy...

ea0016oc6.8 | Metabolism and cardiovascular | ECE2008

Chronic prostaglandin excess results in adipose tissue wasting through increased substrate utilization

Vegiopoulos Alexandros , Chichelnitskiy Evgeny , Ostertag Anke , Diaz Mauricio Berriel , Muller-Decker Karin , Herzig Stephan

Disruption of the balance in energy homeostasis and substrate metabolism can lead to obesity and the metabolic syndrome on one hand and body wasting in cachexia associated with cancer and other chronic diseases on the other hand. Indirect evidence suggests that prostaglandins (PGs), products of the cyclooxygenase (COX) pathway, are involved in the regulation of metabolic processes under physiological conditions or during disease, in particular cancer cachexia. However, the dir...

ea0011p182 | Clinical practise and governance | ECE2006

Impaired quality of life in patients with adrenal insufficiency – evidence that improved glucocorticoid replacement strategies are needed

Hahner S , Loeffler M , Arlt W , Decker O , Koschker AC , Weismann D , Fassnacht M , Allolio B

A recent study has reported impaired subjective health status (SHS) in 79 patients with primary adrenal insufficiency (AI) despite routine steroid replacement1. Here we have performed a survey in a large cohort of patients with primary and secondary AI. 348 patients (148 outpatients and 200 registered participants of the self-help network for adrenal and pituitary diseases) were contacted by mail. 256 (74%) agreed to participate and received a disease specific and 3...